Trial Profile
A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Mirzotamab clezutoclax (Primary) ; Docetaxel; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors AbbVie
- 26 Oct 2023 Planned End Date changed from 1 Nov 2023 to 31 Mar 2024.
- 26 Oct 2023 Planned primary completion date changed from 1 Nov 2023 to 31 Mar 2024.
- 06 Jun 2023 Results (As of November 18, 2022, n=78) assessing safety and efficacy of Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology